- Home
- DFDV vs MRVI Comparison
DFDV vs MRVI Comparison
Compare DFDV & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFDV
- MRVI
- Stock Information
- Founded
- DFDV 2018
- MRVI 2014
- Country
- DFDV United States
- MRVI United States
- Employees
- DFDV N/A
- MRVI N/A
- Industry
- DFDV Finance: Consumer Services
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- DFDV Finance
- MRVI Health Care
- Exchange
- DFDV Nasdaq
- MRVI Nasdaq
- Market Cap
- DFDV 330.2M
- MRVI 376.2M
- IPO Year
- DFDV N/A
- MRVI 2020
- Fundamental
- Price
- DFDV $15.79
- MRVI $3.09
- Analyst Decision
- DFDV Buy
- MRVI Hold
- Analyst Count
- DFDV 1
- MRVI 9
- Target Price
- DFDV $45.00
- MRVI $4.54
- AVG Volume (30 Days)
- DFDV 2.3M
- MRVI 1.4M
- Earning Date
- DFDV 11-05-2025
- MRVI 11-06-2025
- Dividend Yield
- DFDV N/A
- MRVI N/A
- EPS Growth
- DFDV N/A
- MRVI N/A
- EPS
- DFDV 1.17
- MRVI N/A
- Revenue
- DFDV $3,520,660.00
- MRVI $219,830,000.00
- Revenue This Year
- DFDV $70.03
- MRVI N/A
- Revenue Next Year
- DFDV $142.86
- MRVI $7.23
- P/E Ratio
- DFDV $13.47
- MRVI N/A
- Revenue Growth
- DFDV 97.13
- MRVI N/A
- 52 Week Low
- DFDV $0.49
- MRVI $1.67
- 52 Week High
- DFDV $53.88
- MRVI $8.54
- Technical
- Relative Strength Index (RSI)
- DFDV 47.47
- MRVI 63.52
- Support Level
- DFDV $14.93
- MRVI $2.59
- Resistance Level
- DFDV $16.35
- MRVI $3.23
- Average True Range (ATR)
- DFDV 1.05
- MRVI 0.20
- MACD
- DFDV 0.00
- MRVI 0.03
- Stochastic Oscillator
- DFDV 29.98
- MRVI 70.42
About DFDV DeFi Development Corp. Common Stock
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.